CSPC Group (01093): Recombinant all-human anti-ACTRIIA/IIB monoclonal antibody (JMT206) approved for clinical trial in the US

Zhitong Finance App News, Shiyao Group (01093) announced that the recombinant all-human anti-ActriIIA/IIb monoclonal antibody (JMT206) (this product) developed by the Group has been approved by the US Food and Drug Administration (FDA) and can conduct clinical trials in the US. The product was also approved by the State Drug Administration of the People's Republic of China to conduct clinical trials in China in November 2025.

This product can simultaneously specifically bind activin receptor type IIA (ActRIIa) and type IIB (ActRIIb) to block the binding of activin A (Activin A), myostatin (GDF8), and growth differentiation factor 11 (GDF11) to activin receptor type II (ActRII), thereby inhibiting the activation of downstream signaling pathways, reducing muscle loss, and promoting skeletal muscle maintenance and growth to achieve the effect of muscle gain and fat loss. At the same time, this product can also help GLP-1 receptor agonists achieve higher quality weight loss effects. The approved clinical indication is weight management for people who are obese or overweight with at least one weight-related complication.

Preclinical studies have shown that the product shows high bioavailability and good efficacy and safety, and has high clinical development value.